+868.4%
CVNA vs MRNA
+554.4%
+313.9%
-99.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.6% | +5.4% | -7.0% | -2.2% |
| 7D | -7.3% | -1.1% | -6.2% | -7.2% |
| 30D | -4.6% | +126.1% | -130.7% | -20.3% |
| 3M | +2.0% | +190.0% | -188.1% | -19.0% |
| 6M | +11.7% | +157.2% | -145.5% | -9.9% |
| YTD | -18.1% | +388.2% | -406.3% | -41.0% |
| 1Y | -2.4% | +467.0% | -469.4% | -32.3% |
| 3Y | +580.6% | +36.1% | +544.5% | +466.6% |
| 5Y | +4.9% | -68.0% | +72.8% | -6.6% |
| All | +868.4% | +554.4% | +313.9% | +799.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling